A pharmacokinetic comparison of generic tablets containing bisoprolol with the innovator formulation in healthy volunteers.
Jovanović
Dusan
D
Institute of Toxicology, Pharmacology and Clinical Pharmacology, National Poison Control Centre, Belgrade, Serbia. NCKTVMA@EUnet.yu
Cusić
Slavko
S
Rancić
Dragana
D
Srnić
Danica
D
Perković-Vukcević
Natasa
N
D000284:Administration, Oral; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D000328:Adult; D019540:Area Under Curve; D001682:Biological Availability; D017298:Bisoprolol / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D018592:Cross-Over Studies; D016568:Drugs, Generic / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D021241:Spectrometry, Mass, Electrospray Ionization / Q000379:methods; D013607:Tablets; D013810:Therapeutic Equivalency; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D016568:Drugs, Generic; D013607:Tablets; D017298:Bisoprolol